<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Neurol</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Neurol</journal-id>
      <journal-title-group>
        <journal-title>BMC Neurology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2377</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27506761</article-id>
      <article-id pub-id-type="pmc">4977691</article-id>
      <article-id pub-id-type="publisher-id">647</article-id>
      <article-id pub-id-type="doi">10.1186/s12883-016-0647-7</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Applied multimodal diagnostics in a case of presenile dementia</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4499-7861</contrib-id>
          <name>
            <surname>Sch&#xF6;necker</surname>
            <given-names>Sonja</given-names>
          </name>
          <address>
            <email>sonja.schoenecker@med.uni-muenchen.de</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brendel</surname>
            <given-names>Matthias</given-names>
          </name>
          <address>
            <email>matthias.brendel@med.uni-muenchen.de</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Huber</surname>
            <given-names>Marion</given-names>
          </name>
          <address>
            <email>m.huber@med.uni-muenchen.de</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vollmar</surname>
            <given-names>Christian</given-names>
          </name>
          <address>
            <email>christian.vollmar@med.uni-muenchen.de</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Huppertz</surname>
            <given-names>Hans-Juergen</given-names>
          </name>
          <address>
            <email>hans-juergen.huppertz@swissepi.ch</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Teipel</surname>
            <given-names>Stefan</given-names>
          </name>
          <address>
            <email>stefan.teipel@med.uni-rostock.de</email>
          </address>
          <xref ref-type="aff" rid="Aff4">4</xref>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Okamura</surname>
            <given-names>Nobuyuki</given-names>
          </name>
          <address>
            <email>nookamura@med.tohoku.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Levin</surname>
            <given-names>Johannes</given-names>
          </name>
          <address>
            <email>johannes.levin@med.uni-muenchen.de</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rominger</surname>
            <given-names>Axel</given-names>
          </name>
          <address>
            <email>axel.rominger@med.uni-muenchen.de</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Danek</surname>
            <given-names>Adrian</given-names>
          </name>
          <address>
            <email>adrian.danek@med.uni-muenchen.de</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Neurology, Ludwig-Maximilians University, Munich, Germany </aff>
        <aff id="Aff2"><label>2</label>Department of Nuclear Medicine, Ludwig-Maximilians University, Munich, Germany </aff>
        <aff id="Aff3"><label>3</label>Swiss Epilepsy Center, Zurich, Switzerland </aff>
        <aff id="Aff4"><label>4</label>Department of Psychosomatic Medicine, University of Rostock, Rostock, Germany </aff>
        <aff id="Aff5"><label>5</label>German Center for Neurodegenerative Diseases, Rostock, Germany </aff>
        <aff id="Aff6"><label>6</label>Department of Pharmacology, Tohoku University School of Medicine, Sendai, Japan </aff>
        <aff id="Aff7"><label>7</label>German Center for Neurodegenerative Diseases, Munich, Germany </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>9</day>
        <month>8</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>9</day>
        <month>8</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2016</year>
      </pub-date>
      <volume>16</volume>
      <elocation-id>131</elocation-id>
      <history>
        <date date-type="received">
          <day>2</day>
          <month>3</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>26</day>
          <month>7</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s). 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Alzheimer&#x2019;s disease (AD) is the most common cause of dementia in the elderly. The possibility of disease-modifying strategies has evoked a need for early and accurate diagnosis. To improve the accuracy of the clinical diagnosis of AD, biomarkers like cerebrospinal fluid (CSF) and neuroimaging techniques like magnetic resonance imaging (MRI) and positron emission tomography (PET) have been incorporated into the diagnostic guidelines of AD.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>In this case report we outline in reference to one of our patients with presenile dementia the current approaches to the diagnosis of AD. The patient was a 59-year old woman presenting with progressive memory decline. CSF-A&#x3B2;<sub>42</sub> was normal while P-tau was slightly increased. FDG-PET indicated a pattern typical for AD, amyloid-PET showed an extensive global amyloid load, and tau-PET depicted a pronounced hippocampal tracer accumulation. The MRI scan was rated as normal at routine diagnostics, however quantitative volumetric analysis revealed significant atrophy especially of the parietal lobe. The combination of biomarkers and neuroimaging techniques was therefore suggestive of an underlying AD pathology.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>To enable early and accurate diagnosis of AD and thereby also patient recruitment for anti-tau or anti-&#x3B2;-amyloid therapeutic trials, a combination of biomarkers and neuroimaging techniques seems useful.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Case report</kwd>
        <kwd>Alzheimer&#x2019;s disease</kwd>
        <kwd>Biomarkers</kwd>
        <kwd>CSF</kwd>
        <kwd>MRI</kwd>
        <kwd>FDG-PET</kwd>
        <kwd>tau-PET</kwd>
        <kwd>Amyloid-PET</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Alzheimer&#x2019;s disease (AD) is the most common cause of dementia and is estimated to affect 106.8 million people worldwide by the year 2050 [<xref ref-type="bibr" rid="CR1">1</xref>]. It is clinically characterized by progressive memory and language impairment, functional and behavioural disturbances and visuospatial deficits [<xref ref-type="bibr" rid="CR2">2</xref>]. A definite diagnosis of AD still relies on post-mortem histopathological detection of intracellular neurofibrillary tangles and extracellular amyloid plaques [<xref ref-type="bibr" rid="CR3">3</xref>]. It is widely acknowledged that histopathological changes start years before clinical manifestation of the disease [<xref ref-type="bibr" rid="CR4">4</xref>]. As first disease modifying therapies are approaching early and accurate diagnosis of AD becomes increasingly important [<xref ref-type="bibr" rid="CR5">5</xref>]. Therefore the National Institute on Aging and the Alzheimer&#x2019;s Association have revised the criteria for the diagnosis of AD [<xref ref-type="bibr" rid="CR6">6</xref>]. To assess the probability of an underlying AD pathology biomarkers of the disease and neuroimaging techniques have been incorporated into the diagnostic guidelines of AD. Here we present an exemplary case of presenile dementia based on which we discuss the approaches to the diagnosis of AD.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>A 59&#xA0;year old retired attorney, with 18&#xA0;years of education presented with a three year history of progressive memory decline. For about one year she hadn&#x2019;t been able to do the shopping or the cooking. No behavioural changes, language impairment, severe fluctuations of attention and alertness, recurrent visual hallucinations or history of repetitive brain trauma were reported. Family history was positive, her mother as well as an uncle had developed late-onset dementia.</p>
      <p>The Mini-Mental-State Examination which had been performed three years ago because of subjective memory impairment had been rated as normal. For neuropsychological testing we applied the CERAD plus battery additionally including Trail Making Test A and B as well as verbal fluency tests. The scores of almost all domains of the CERAD plus battery were at least &#x2212;1.37 standard deviations below the age- and education-adjusted norm values. She scored 24 out of 30 points in the Mini-Mental-State Examination. Naming (Boston-Naming-test) was intact whereas phonemic verbal fluency was slightly (11 words in 1&#xA0;min) and semantic fluency (9 words in 1&#xA0;min) was highly reduced. Memory was highly impaired. She displayed intrusions and showed a reduced performance of word list recall and recognition. Constructional practice was impaired as well. Results of the Trail-Making Test showed reduced visual attention as well as reduced speed of processing. Cognitive flexibility measured by Trail-Making-Test B was also poor.</p>
      <p>At first presentation the neurological examination was normal. In particular no manifest or latent paresis and no sensory deficit could be detected. Deep tendon reflexes were mildly hypoactive without any pathological reflexes. Cranial nerves were also intact. There was no evidence of extrapyramidal features.</p>
      <p>Laboratory tests for metabolic causes of dementia, for example for vitamin B<sub>12</sub>, thyroid, liver and renal function, thiamine level and folate were within the normal range. P-tau (66&#xA0;pg/ml, N&#x2009;&lt;&#x2009;61&#xA0;pg/ml) in cerebrospinal fluid (CSF) was only slightly increased, whereas total Tau (293&#xA0;pg/ml, N&#x2009;&lt;&#x2009;500&#xA0;pg/ml) and A&#x3B2;<sub>42</sub> (1171&#xA0;pg/ml, N&#x2009;&gt;&#x2009;500&#xA0;pg/ml) were normal. All other CSF parameters were within the normal range.</p>
      <p>The MRI scan which had been performed three years ago as well as the MRI scan at first presentation were interpreted as normal at visual inspection. Especially no sign of global or regional atrophy could be detected. However, atlas-based volumetric MRI analysis [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>] showed a significant reduction especially of temporal and parietal lobe volumes. Z-scores for the hippocampal and parietal volumes compared to healthy controls were &#x2212;2.9 and &#x2212;4.2 respectively (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Volumetric MRI analysis of our patient&#x2019;s (dark arrow) hippocampus and parietal lobe compared to AD patients and age-matched healthy controls after intracranial-volume correction. Z-scores of hippocampal and parietal lobe volume compared to healthy controls were &#x2212;2.9 and &#x2212;4.2 respectively. Our patient&#x2019;s datapoint lay within the 95&#xA0;% confidence region of Alzheimer&#x2019;s disease and outside the 95&#xA0;% confidence region of healthy controls and was therefore automatically assigned to the Alzheimer&#x2019;s disease group</p></caption><graphic xlink:href="12883_2016_647_Fig1_HTML" id="MO1"/></fig></p>
      <p>Moreover, a quantitative analysis based on voxel-wise z-score analysis of patient grey matter segments and grey matter segments from an age and sex-matched control sample after bias correction and spatial normalization in a common standard space following an established method [<xref ref-type="bibr" rid="CR9">9</xref>] showed a slight asymmetry with more pronounced atrophy of rightsided parietotemporal cortical areas (voxel based grey matter reduction z&#x2009;&gt;&#x2009;&#x2212;1.96) (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). It has to be noted that for the quantitative analysis, data of the comparison group came from another MRI scanner than the scan of the patient. Acquisition parameters were harmonized between scanners to accommodate possible scanner effects.<fig id="Fig2"><label>Fig. 2</label><caption><p>Positron emission tomography of the brain with F-18-labeled fluorodeoxyglucose (FDG-PET) and three-dimensional surface representation of brain regions with grey matter reduction of our 59-year-old AD patient compared to 18 healthy controls. Top: regional uptake of radiolabelled glucose; the left lateral, left medial and right lateral views of the brain are presented. Middle: regional metabolic reduction compared to age-matched healthy controls according to the methodology of Minoshima et al. [<xref ref-type="bibr" rid="CR53">53</xref>]. There is an asymmetric metabolic reduction parietotemporal and in posterior cingulate cortex with a more pronounced reduction of glucose metabolism in the right hemisphere. Bottom: color-coded brain matter reduction. Z-values of grey matter reduction are projected on T1-weighted, averaged brain surface of healthy control subjects</p></caption><graphic xlink:href="12883_2016_647_Fig2_HTML" id="MO2"/></fig></p>
      <p>Fluorodeoxyglucose-PET (FDG-PET) showed an asymmetric reduction of brain glucose metabolism of parietal and temporal cortical areas with a more pronounced reduction of glucose metabolism in the right hemisphere. In addition glucose metabolism of the posterior cingulate cortex was significantly reduced (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>).</p>
      <p>The patient underwent a florbetaben-PET (FBB-PET) scan which showed extensive FBB retention that was greater in parietotemporal, frontal and posterior cingulate/precuneus cortex and less pronounced in the occipital cortex. Basal ganglia were also slightly affected (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>A&#x3B2; and tau imaging with FBB (top) and THK-5351 (bottom) of our 59&#xA0;year old patient with Alzheimer&#x2019;s disease. FBB and THK-5351 binding patterns demonstrate the different distributions of A&#x3B2; and tau deposits in the brain of our Alzheimer&#x2019;s disease patient. FBB-PET scan revealed a massive global amyloid load with a pronounced FBB retention in parietotemporal, frontal and posterior cingulate/precuneal cortices. In contrast THK-5351 retention was markedly elevated in the hippocampus, whereas onlya slightly increased THK-5351 retention was observed in parietotemporal cortical areas</p></caption><graphic xlink:href="12883_2016_647_Fig3_HTML" id="MO3"/></fig></p>
      <p>The tau-PET scan with THK-5351 on the other hand showed high tracer retention in both hippocampi as well as moderately increased tracer retention in parietotemporal cortical areas. There was no elevated tracer retention in other cortical areas (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>).</p>
    </sec>
    <sec id="Sec3">
      <title>Conclusions</title>
      <p>As our patient presented with a three year history of cognitive decline that interfered with activities of daily living and scored low in almost all domains of the CERAD plus battery a clinical diagnosis of AD was made [<xref ref-type="bibr" rid="CR6">6</xref>]. Because of the presenile age at onset and the positive family history a monogenic form of AD might be possible. Genetic testing could have excluded conditions mimicking sporadic AD-like dementia. Our patient however refused genetic testing. Sensitivity and specificity of the clinical diagnosis of AD compared to post-mortem histopathological diagnosis ranges from 70.9 to 87.3&#xA0;% and from 44.3 to 70.8&#xA0;% respectively [<xref ref-type="bibr" rid="CR10">10</xref>]. The combination of biomarkers and neuroimaging techniques was suggestive of an underlying AD pathology. In absence of a neuropathological confirmation of AD pathology, a definite diagnosis of AD, however, was not possible. The most important alternative diagnosis in a case of presenile dementia are dementia with Lewy bodies (DLB), frontotemporal dementia with memory impairment (FTD) and chronic traumatic encephalopathy (CTE). As our patient had no pronounced variation in attention and alertness, reported no recurrent visual hallucinations and displayed no features of parkinsonism the core features of DLB were not fulfilled [<xref ref-type="bibr" rid="CR11">11</xref>]. Furthermore no progressive deterioration of personality or social comportment was reported and there was no evidence of progressive language impairment. Therefore there was no clinical evidence for behavioural variant frontotemporal dementia [<xref ref-type="bibr" rid="CR12">12</xref>] or primary progressive aphasia [<xref ref-type="bibr" rid="CR13">13</xref>]. As there was no history of recurrent impacts to the head or body, CTE seemed unlikely as well [<xref ref-type="bibr" rid="CR14">14</xref>]. Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref> summarizes biomarker and neuroimaging findings in autopsy confirmed cases of DLB, FTD and CTE. [References in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>: [<xref ref-type="bibr" rid="CR15">15</xref>&#x2013;<xref ref-type="bibr" rid="CR30">30</xref>]]. In the following the current diagnostic approaches used in the diagnosis of AD are illustrated with reference to our 59-year old patient.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of biomarker and neuroimaging findings in autopsy confirmed DLB, FTD and CTE cases</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Population</th><th>CSF biomarker/Ligand</th><th>Major findings</th></tr></thead><tbody><tr><td colspan="4">CSF</td></tr><tr><td rowspan="2">&#x2003;Clark et al.(15]</td><td rowspan="2">60&#xA0;AD, 10 FTD, 3 DLB</td><td rowspan="2">total Tau, A&#x3B2;42</td><td>higher total tau in AD compared to FTD and DLB</td></tr><tr><td>A&#x3B2;42 reduced in AD compared to FTD but not compared to DLB</td></tr><tr><td rowspan="2">&#x2003;Slaets et al. [<xref ref-type="bibr" rid="CR16">16</xref>]</td><td rowspan="2">30&#xA0;AD,<break/>13 DLB with SP, 5 DLB without SP<break/>30&#xA0;AD,<break/>9 DLB with NFT, 9 DLB without NFT</td><td>P-Tau, total Tau, A&#x3B2;42</td><td>A&#x3B2;42 reduced in AD and DLB with SP compared to DLB without SP<break/>no difference in A&#x3B2;42 levels of AD and DLB with SP patients</td></tr><tr><td>P-Tau, total Tau, A&#x3B2;42</td><td>P-Tau higher in AD compared to DLB with and without NFT<break/>no difference in P-Tau levels of DLB with and without NFT<break/>no difference of total Tau between the DLB subgroups and AD</td></tr><tr><td>&#x2003;Koopmann et al. [<xref ref-type="bibr" rid="CR17">17</xref>]</td><td>95&#xA0;AD, 18 DLB, 10 FTD</td><td>P-Tau, total Tau, A&#x3B2;42</td><td>P-Tau cut-off for differentiating AD from FTD 35.3&#xA0;pg/ml, from DLB 52.8&#xA0;pg/ml<break/>total Tau level: AD&#x2009;&gt;&#x2009;DLB&#x2009;&gt;&#x2009;FTD<break/>A&#x3B2;42 level: AD&#x2009;&lt;&#x2009;DLB&#x2009;=&#x2009;FTD</td></tr><tr><td>&#x2003;Bian et al. [<xref ref-type="bibr" rid="CR18">18</xref>]</td><td>AD 19, FTD 30</td><td>total Tau, A&#x3B2;42</td><td>total Tau and tau/A&#x3B2;42 ratio lower in FTD than in AD</td></tr><tr><td>&#x2003;Toledo et al. [<xref ref-type="bibr" rid="CR19">19</xref>]</td><td>71&#xA0;AD, 29 FTD</td><td>P-Tau, total Tau, A&#x3B2;42</td><td>high sensitivity and specificity of combined CSF biomarkers in classifying AD against FTD<break/>P-Tau and total Tau higher in AD compared to FTD<break/>A&#x3B2;42 lower in AD compared to FTD</td></tr><tr><td colspan="4">MRI</td></tr><tr><td>&#x2003;Vemuri et al. [<xref ref-type="bibr" rid="CR20">20</xref>]</td><td>48&#xA0;AD, 47 FTD, 20 DLB</td><td/><td>atrophy pattern in AD: temporoparietal association cortices and medial temporal lobe<break/>FTD: frontal and temporal lobes<break/>DLB: bilateral amygdalae, dorsal midbrain, inferior temporal lobe</td></tr><tr><td>&#x2003;Rabinovici et al. [<xref ref-type="bibr" rid="CR21">21</xref>]</td><td>11&#xA0;AD, 18 FTD</td><td/><td>atrophy in AD: posterior temporoparietal and occipital atrophy<break/>atrophy in FTD: medial prefrontal and medial temporal cortex, insula, hippocampus, amygdala</td></tr><tr><td>&#x2003;Burton et al. [<xref ref-type="bibr" rid="CR22">22</xref>]</td><td>11&#xA0;AD, 23 DLB</td><td/><td>pronounced medial temporal lobe atrophy in AD compared to DLB patients</td></tr><tr><td>&#x2003;Kantarci et al. [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td>2&#xA0;AD, 3DLB</td><td/><td>more pronounced hippocampal atrophy in AD compared to DLB</td></tr><tr><td>&#x2003;McKee et al. [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td>1 CTE</td><td/><td>generalized cortical atrophy, enlargement of ventricles, cavum septum pellucidum</td></tr><tr><td colspan="4">&#x2003;FDG-PET</td></tr><tr><td>&#x2003;Minoshima et al. [<xref ref-type="bibr" rid="CR25">25</xref>]</td><td>10&#xA0;AD, 4 DLB</td><td/><td>AD and DLB: hypometabolism in posterior cingulate, parietotemporal and frontal association&#xA0;cortices<break/>additional occipital hypometabolism in DLB</td></tr><tr><td>&#x2003;Albin et al. [<xref ref-type="bibr" rid="CR26">26</xref>]</td><td>3&#xA0;AD-DLB, 3 DLB</td><td/><td>compared to AD additional hypometabolism in occipital association and primary visual cortex</td></tr><tr><td>&#x2003;Kantarci et al. [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td>2&#xA0;AD, 3 DLB</td><td/><td>low occipital FDG-uptake in 1&#xA0;AD patient and all DLB patients</td></tr><tr><td>&#x2003;Foster et al. [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td>31&#xA0;AD, 14 FTD</td><td/><td>AD: temporoparietal and posterior cingulate hypometablism<break/>FTD: frontal, anterior cingulate and anterior temporal hypometabolism</td></tr><tr><td colspan="4">&#x2003;Amyloid-PET</td></tr><tr><td rowspan="2">&#x2003;Kantarci et al. [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td rowspan="2">2&#xA0;AD, 3 DLB</td><td rowspan="2">PiB</td><td>high global cortical PiB retention in one AD patient, low global cortical PiB in the other</td></tr><tr><td>2 DLB patients with borderline PiB retention, 1 DLB patient with high PiB retention</td></tr><tr><td>&#x2003;Bacskai et al. [<xref ref-type="bibr" rid="CR28">28</xref>]</td><td>1 DLB</td><td>PiB</td><td>tracer uptake in posterior cingulate, precuneus, posterior parietal,<break/>middle and inferior temporal, insular, lateral and orbital frontal cortices</td></tr><tr><td>&#x2003;Rabinovici et al. [<xref ref-type="bibr" rid="CR29">29</xref>]</td><td>3&#xA0;AD, 7 FTD</td><td>PiB</td><td>higher PiB retention in AD compared to FTD<break/>better classification accuracy of PiB-PET compared to FDG-PET</td></tr><tr><td colspan="4">Tau-PET</td></tr><tr><td>&#x2003;Ghetti et al. [<xref ref-type="bibr" rid="CR30">30</xref>]</td><td>1 FTD</td><td>T807</td><td>elevated tracer uptake in anterior, temporal and parietal cortex as well as basal ganglia</td></tr></tbody></table><table-wrap-foot><p>
<italic>CSF</italic> cerebrospinal fluid, <italic>AD</italic> Alzheimer&#x2019;s disease, <italic>FTD</italic> frontotemporal dementia, <italic>DLB</italic> dementia with lewy bodies, <italic>CTE</italic> chronic traumatic encephalopathy, <italic>SP</italic> senile plaque, <italic>NFT</italic> neurofibrillary tangles, <italic>MRI</italic> magnetic resonance imaging, <italic>PET</italic> positron emission tomography, <italic>FDG</italic> fluorodeoxyglucose</p></table-wrap-foot></table-wrap></p>
      <p>Neuropsychological testing is commonly used as an aid in diagnosing AD. In our patient the scores of almost all domains of the CERAD plus battery were well below average. Memory was most severely affected. As the earliest pathological changes in AD occur in medial temporal lobe structures [<xref ref-type="bibr" rid="CR31">31</xref>] episodic memory is usually the first cognitive ability to decline, typically followed, like in our case by additional deficits in language and semantic knowledge, executive functions, working memory, attention and visuospatial abilities [<xref ref-type="bibr" rid="CR32">32</xref>].</p>
      <p>Results of laboratory testing for example for vitamin B<sub>12,</sub> thyroid function, thiamine level and folate, were within the normal range. Laboratory testing should be performed in every AD patient to rule out metabolic causes of dementia.</p>
      <p>CSF did not suggest malignancy, neuroinflammation or infection. P-tau that reflects the intensity of neuronal degeneration was slightly increased. Interestingly, although amyloid-PET revealed an extensive global amyloid load, CSF-A&#x3B2;<sub>42</sub> on the other hand was normal. It has been shown that amyloid load at autopsy of AD patients is inversely correlated to CSF-A&#x3B2;<sub>42</sub> whereas tau load is positively correlated to CSF P-tau and total tau [<xref ref-type="bibr" rid="CR33">33</xref>]. Yet although CSF and amyloid-PET measurements of A&#x3B2;<sub>42</sub> are consistent in the majority of patients a dissociation between A&#x3B2;<sub>42</sub> measurements is not uncommon [<xref ref-type="bibr" rid="CR34">34</xref>]. Especially the combination of CSF biomarkers may increase diagnostic certainty of AD pathology. Yet, as CSF biomarkers do not change during the clinical phase of AD, they cannot be used as markers of disease progression [<xref ref-type="bibr" rid="CR35">35</xref>]. In comparison to AD patients, DLB and FTD patients present significantly lower P-tau and total tau levels [<xref ref-type="bibr" rid="CR17">17</xref>]. There is however some overlap in CSF P-tau and total tau between AD, DLB and FTD patients. A&#x3B2;<sub>42</sub> is generally decreased in DLB. Most studies could not define valuable CSF A&#x3B2;<sub>42</sub> cut-off scores for differentiation of DLB from AD [<xref ref-type="bibr" rid="CR36">36</xref>]. CSF A&#x3B2;<sub>42</sub> levels of FTD patients on the other hand are significantly higher compared to AD patients [<xref ref-type="bibr" rid="CR18">18</xref>]. The combination of CSF P-tau, total tau and A&#x3B2;<sub>42</sub> has shown high diagnostic sensitivity and specificity in distinguishing AD from DLB and FTD patients. In CTE one would expect normal CSF A&#x3B2;<sub>42</sub> levels and an elevated P-tau/total tau ratio [<xref ref-type="bibr" rid="CR14">14</xref>]. Large biomarker studies on autopsy confirmed CTE cases however are lacking. AS CSF P-tau was only slightly increased while CSF total tau and A&#x3B2;<sub>42</sub> were within the normal range, CSF analysis was not suggestive of an underlying AD pathology in our case.</p>
      <p>The MRI scan was interpreted as normal at routine diagnostics, especially no sign of normal-pressure hydrocephalus, cerebrovascular disease, tumours or regional/global atrophy could be detected. Volumetric MRI analysis however revealed significant atrophy of the parietal and temporal lobe, especially of the hippocampus, and may therefore be useful to obtain rater- independent and objective results [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Comparison of atrophy patterns can differentiate AD patients with a high sensitivity and specificity from healthy controls and other dementia syndromes like DLB and FTD [<xref ref-type="bibr" rid="CR20">20</xref>]. In DLB significant gray matter loss is detectable in bilateral amygdalae, the middle temporal lobe as well as the dorsal ponto-mesencephalic junction area [<xref ref-type="bibr" rid="CR20">20</xref>]. In FTD patients atrophy is normally restricted to the frontal and temporal lobes, with relative sparing of the parietal and occipital lobes. MRI may also be useful to detect neuropathological changes observed in CTE like whole brain atrophy or cavum septum pellucidum with occasional fenestration [<xref ref-type="bibr" rid="CR24">24</xref>]. In our case volumetric MRI analysis showed a typical AD atrophy pattern with pronounced atrophy of the parietal and temporal lobe, especially the hippocampus, and therefore supported the diagnosis of AD. In Alzheimer&#x2019;s disease patients, especially hippocampal atrophy (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>) seems to be highly correlated with episodic memory impairment [<xref ref-type="bibr" rid="CR37">37</xref>].</p>
      <p>In the FDG-PET scan (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>) the typical AD pattern consisting of a reduction of cerebral glucose metabolism in precuneus, posterior cingulate and parietotemporal association cortices [<xref ref-type="bibr" rid="CR38">38</xref>] could be detected. In comparison, DLB patients show an additional significant metabolic reduction in the occipital cortex, particularly the primary visual cortex, which distinguishes DLB with a high sensitivity and specificity from AD patients [<xref ref-type="bibr" rid="CR25">25</xref>]. FTD on the other hand causes hypometabolism in the frontal lobes, the anterior temporal cortex and anterior cingulate cortex [<xref ref-type="bibr" rid="CR27">27</xref>]. FDG-PET studies that evaluated glucose metabolism in subjects with repetitive brain trauma have shown inconsistent findings [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. In summary, FDG-PET clearly supported AD as the most probable diagnosis in our case. Like structural MRI, FDG-PET represents a marker of neuronal injury. Retrospective investigations showed a sensitivity of 84&#xA0;% and a specificity of 74&#xA0;% for FDG-PET in predicting post-mortem AD pathology at autopsy [<xref ref-type="bibr" rid="CR41">41</xref>]. FDG-PET thereby outperformed the initial clinical evaluation. Furthermore, FDG-PET seems to be a suitable predictor of conversion to AD in patients with mild cognitive impairment [<xref ref-type="bibr" rid="CR42">42</xref>].</p>
      <p>Amyloid- and tau-Pet represent new diagnostic tools. To present a definite diagnosis of AD relies on post-mortem histopathology. Yet these new imaging techniques permit non-invasive visualization and quantification of the two histological hallmarks of the disease.</p>
      <p>Amyloid-PET showed a characteristic increase of tracer uptake in cortical regions known to have a high amount of amyloid burden in AD, i.e. frontal, parietal and lateral temporal cortex (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>). DLB patients can show a similar pattern yet with lower amount of A&#x3B2; ligand binding compared with AD patients [<xref ref-type="bibr" rid="CR43">43</xref>]. FTD patients on the other hand display low cortical tracer retention such that amyloid PET has shown high accuracy in discriminating AD from FTD [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Variable degrees of diffuse &#x3B2;-amyloid can be detected in about 47&#xA0;% of autopsy confirmed CTE cases [<xref ref-type="bibr" rid="CR46">46</xref>]. Amyloid-PET may therefore differentiate between CTE and AD by identifying different amyloid-deposition patterns. Further studies are needed to determine the topography of &#x3B2;-amyloid depositions in CTE. Showing a high amount of tracer uptake in parietotemporal, frontal and posterior cingulate/precuneus cortex, FBB-PET was suggestive for AD in our case. Recent phase III studies in which the in-vivo uptake of 18-F-labelled amyloid tracers was compared to post-mortem amyloid load showed a sensitivity and specificity of 88 to 92&#xA0;%, and 88 to 100&#xA0;% respectively for the detection of amyloid deposits in AD patients [<xref ref-type="bibr" rid="CR47">47</xref>&#x2013;<xref ref-type="bibr" rid="CR49">49</xref>]. As amyloid deposition probably represents a very early event in the course of the disease that occurs years before onset of dementia symptoms, amyloid-PET may allow early and even presymptomatic diagnosis [<xref ref-type="bibr" rid="CR4">4</xref>].</p>
      <p>Increased tau-tracer retention could be detected in parietotemporal cortical areas, especially in the hippocampus (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>). In contrast to amyloid-PET the sensitivity and specificity of tau-PET imaging have yet to be determined. Post-mortem studies have shown that the amount of tau deposition is highly related to the severity of dementia [<xref ref-type="bibr" rid="CR50">50</xref>]. In addition to aiding in the early and differential diagnosis of Alzheimer&#x2019;s disease tau-PET may therefore serve as a marker of disease progression. Recently, first experiences with tau-PET in DLB were reported [<xref ref-type="bibr" rid="CR51">51</xref>]. Tau deposition is elevated in some cases of DLB, especially in the inferior temporal region. Tau-PET scans may be positive in some variants of FTD. A first case report of a P301L <italic>MAPT</italic> mutation carrier showing elevated tau tracer uptake in frontal, anterior temporal and parietal cortex as well as in basal ganglia has been published [<xref ref-type="bibr" rid="CR30">30</xref>]. Hitherto a single case report of a patient with a clinical diagnosis of CTE who underwent tau-PET imaging has been published [<xref ref-type="bibr" rid="CR52">52</xref>]. Increased tracer uptake could be detected in globus pallidus, putamen, hippocampus and substantia nigra. Because of increased tracer retention in basal ganglia the detected distribution of tracer retention seemed more suggestive of progressive supranuclear palsy. However the patient did not manifest the typical clinical symptoms of progressive supranuclear palsy. In summary tau-PET also supported a diagnosis of AD in our case.</p>
      <p>Overall, although CSF A&#x3B2;<sub>42</sub> was normal, the combination of biomarker and neuroimaging findings in this case was still suggestive of AD pathology. Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref> rates the biomarker and neuroimaging findings of our case with respect to possible differential diagnosis.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Rating of biomarker and neuroimaging findings of our case with respect to possible differential diagnosis</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Biomarker/neuroimaging findings</th><th>AD</th><th>FTD</th><th>DLB</th><th>CTE</th></tr></thead><tbody><tr><td>CSF P-tau</td><td>+</td><td>-</td><td>-</td><td>-</td></tr><tr><td>CSF A&#x3B2;42</td><td>-</td><td>O</td><td>-</td><td>O</td></tr><tr><td>MRI - clinical routine</td><td>O</td><td>O</td><td>O</td><td>O</td></tr><tr><td>MRI - voxel-based</td><td>++</td><td>-</td><td>+</td><td>-</td></tr><tr><td>FDG-PET</td><td>++</td><td>-</td><td>O</td><td>-</td></tr><tr><td>amyloid-PET</td><td>++</td><td>-</td><td>+</td><td>+</td></tr><tr><td>tau-PET</td><td>++</td><td>O</td><td>O</td><td>O</td></tr></tbody></table><table-wrap-foot><p>++ highly increases probability, + increases probability, O probability unchanged, &#x2212; decreases probability</p></table-wrap-foot></table-wrap></p>
      <p>As some of the illustrated diagnostic approaches provided converging evidence, e.g. CSF P-tau, MRI, FDG-PET and Tau-PET each indicated an AD typical neuronal degeneration and thereby provided somewhat redundant information, the necessity for a diagnostic algorithm becomes obvious. A sequential diagnostic process where widely available diagnostic tools like neuropsychological testing to establish the diagnosis of a dementia syndrome and laboratory testing to exclude metabolic causes of dementia are performed in a first step may be useful. Such a baseline testing could help to select patients that profit from further diagnostic work-up. In a second step CSF examination and structural MRI may be rational, on the one hand to further exclude potentially treatable causes of dementia like neuroinflammation or normal pressure hydrocephalus and on the other hand to obtain evidence for an AD-related pathological process and AD typical neuronal degeneration. In patients presenting with an atypical clinical course or atypically early age of onset the more expensive nuclear medicine diagnostic techniques FDG-, amyloid- and tau-PET might be useful to differentiate between AD and important differential diagnoses like pseudo-dementia or frontotemporal dementia. They may also serve as markers of disease progression and prognostic markers. Especially tau and amyloid imaging may furthermore be useful for patient recruitment and serve as a surrogate marker for monitoring the efficacy of future anti-tau or anti-amyloid strategies.</p>
    </sec>
    <sec id="Sec4">
      <title>Abbreviations</title>
      <p>AD, Alzheimer&#x2019;s disease; CSF, cerebrospinal fluid; CTE, chronic traumatic encephalopathy; DLB, dementia with lewy bodies; FBB, florbetaben; FDG, fluorodeoxyglucose; FTD, frontotemporal dementia; MRI, magnetic resonance imaging; PET, positron emission tomography</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>&#x115F;</title>
      <p>&#x115F;</p>
      <sec id="FPar1">
        <title>Funding</title>
        <p>No funding was obtained.</p>
      </sec>
      <sec id="FPar2">
        <title>Availability of data and materials</title>
        <p>All data are presented in the manuscript. There are no additional data.</p>
      </sec>
      <sec id="FPar3">
        <title>Authors&#x2019; contributions</title>
        <p>SS coordinated and drafted the manuscript and figures; MB, CV, HJH, ST, NO, AR were involved in imaging acquisition and analyses; MH was involved in patient care; MB, MH, CV, HJH, ST, AR, JL, NO, AD critically revised the manuscript. All authors read and approved the final manuscript.</p>
      </sec>
      <sec id="FPar4">
        <title>Competing interests</title>
        <p>The authors declare that they have no competing interests.</p>
      </sec>
      <sec id="FPar5">
        <title>Consent for publication</title>
        <p>Written informed consent for publication of this Case Report and any accompanying images was obtained from the patient&#x2019;s next of kin, i.e. her husband. A copy of the written consent is available for review to the Editor of this journal.</p>
      </sec>
      <sec id="FPar6">
        <title>Ethics approval and consent to participate</title>
        <p>Not applicable.</p>
      </sec>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brookmeyer</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ziegler-Graham</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Arrighi</surname>
              <given-names>HM</given-names>
            </name>
          </person-group>
          <article-title>Forecasting the global burden of Alzheimer&#x2019;s disease</article-title>
          <source>Alzheimer&#x2019;s &amp; Dementia</source>
          <year>2007</year>
          <volume>3</volume>
          <issue>3</issue>
          <fpage>186</fpage>
          <lpage>191</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jalz.2007.04.381</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cummings</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Alzheimer&#x2019;s Disease</article-title>
          <source>The New England journal of medicine</source>
          <year>2004</year>
          <volume>351</volume>
          <fpage>56</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMra040223</pub-id>
          <pub-id pub-id-type="pmid">15229308</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jellinger</surname>
              <given-names>KA</given-names>
            </name>
          </person-group>
          <article-title>Neuropathology of Dementia Disorders</article-title>
          <source>Journal of Alzheimer&#x2019;s Disease &amp; Parkinsonism</source>
          <year>2014</year>
          <volume>4</volume>
          <fpage>135</fpage>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bateman</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Xiong</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Benzinger</surname>
              <given-names>TLS</given-names>
            </name>
            <name>
              <surname>Fagan</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Goate</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>NC</given-names>
            </name>
            <name>
              <surname>Marcus</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Cairns</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Blazey</surname>
              <given-names>TM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical and Biomarker Changes in Dominantly Inherited Alzheimer&#x2019;s Disease</article-title>
          <source>New England Journal of Medicine</source>
          <year>2012</year>
          <volume>367</volume>
          <issue>9</issue>
          <fpage>795</fpage>
          <lpage>804</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1202753</pub-id>
          <pub-id pub-id-type="pmid">22784036</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bergmans</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>De Strooper</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>&#x3B3;-secretases: from cell biology to therapeutic strategies</article-title>
          <source>The Lancet Neurology</source>
          <year>2010</year>
          <volume>9</volume>
          <issue>2</issue>
          <fpage>215</fpage>
          <lpage>226</lpage>
          <pub-id pub-id-type="doi">10.1016/S1474-4422(09)70332-1</pub-id>
          <pub-id pub-id-type="pmid">20129170</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McKhann</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Knopman</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Chertkow</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hyman</surname>
              <given-names>BT</given-names>
            </name>
            <name>
              <surname>Jack</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Kawas</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Klunk</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>Koroshetz</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Manly</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Mayeux</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>The diagnosis of dementia due to Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease</article-title>
          <source>Alzheimer&#x2019;s &amp; Dementia</source>
          <year>2011</year>
          <volume>7</volume>
          <issue>3</issue>
          <fpage>263</fpage>
          <lpage>269</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jalz.2011.03.005</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huppertz</surname>
              <given-names>H-J</given-names>
            </name>
            <name>
              <surname>Kroell-Seger</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kloeppel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ganz</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Kassubek</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Intra- and interscanner variability of automated voxel-based volumetry based on a 3D probabilistic atlas of human cerebral structures</article-title>
          <source>NeuroImage</source>
          <year>2010</year>
          <volume>49</volume>
          <issue>3</issue>
          <fpage>2216</fpage>
          <lpage>2224</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neuroimage.2009.10.066</pub-id>
          <pub-id pub-id-type="pmid">19878722</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frings</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Yew</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Flanagan</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lam</surname>
              <given-names>BY</given-names>
            </name>
            <name>
              <surname>Hull</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Huppertz</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Hodges</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Hornberger</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Longitudinal grey and white matter changes in frontotemporal dementia and Alzheimer&#x2019;s disease</article-title>
          <source>PloS one</source>
          <year>2014</year>
          <volume>9</volume>
          <issue>3</issue>
          <fpage>e90814</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0090814</pub-id>
          <pub-id pub-id-type="pmid">24595028</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Teipel</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Reuter</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Stieltjes</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Acosta-Cabronero</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ernemann</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Fellgiebel</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Filippi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Frisoni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hentschel</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Jessen</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Multicenter stability of diffusion tensor imaging measures: a European clinical and physical phantom study</article-title>
          <source>Psychiatry research</source>
          <year>2011</year>
          <volume>194</volume>
          <issue>3</issue>
          <fpage>363</fpage>
          <lpage>371</lpage>
          <pub-id pub-id-type="doi">10.1016/j.pscychresns.2011.05.012</pub-id>
          <pub-id pub-id-type="pmid">22078796</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beach</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Monsell</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Phillips</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Kukull</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005&#x2013;2010</article-title>
          <source>Journal of neuropathology and experimental neurology</source>
          <year>2012</year>
          <volume>71</volume>
          <issue>4</issue>
          <fpage>266</fpage>
          <lpage>273</lpage>
          <pub-id pub-id-type="doi">10.1097/NEN.0b013e31824b211b</pub-id>
          <pub-id pub-id-type="pmid">22437338</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McKeith</surname>
              <given-names>IG</given-names>
            </name>
            <name>
              <surname>Dickson</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Lowe</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Emre</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>O&#x2019;Brien</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Cummings</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Duda</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Lippa</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Perry</surname>
              <given-names>EK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium</article-title>
          <source>Neurology</source>
          <year>2005</year>
          <volume>65</volume>
          <issue>12</issue>
          <fpage>1863</fpage>
          <lpage>1872</lpage>
          <pub-id pub-id-type="doi">10.1212/01.wnl.0000187889.17253.b1</pub-id>
          <pub-id pub-id-type="pmid">16237129</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rascovsky</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hodges</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Knopman</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mendez</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kramer</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Neuhause</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>van Swieten</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia</article-title>
          <source>Brain</source>
          <year>2011</year>
          <volume>134</volume>
          <fpage>2456</fpage>
          <lpage>2477</lpage>
          <pub-id pub-id-type="doi">10.1093/brain/awr179</pub-id>
          <pub-id pub-id-type="pmid">21810890</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gorno-Tempini</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Hillis</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Weintraub</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kertesz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mendez</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cappa</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Ogar</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Rohrer</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Black</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Boeve</surname>
              <given-names>BF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Classification of primary progressive aphasia and its variants</article-title>
          <source>Neurology</source>
          <year>2011</year>
          <volume>76</volume>
          <fpage>1006</fpage>
          <lpage>1014</lpage>
          <pub-id pub-id-type="doi">10.1212/WNL.0b013e31821103e6</pub-id>
          <pub-id pub-id-type="pmid">21325651</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Montenigro</surname>
              <given-names>PH</given-names>
            </name>
            <name>
              <surname>Baugh</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Daneshvar</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Mez</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Budson</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Au</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Katz</surname>
              <given-names>DI</given-names>
            </name>
            <name>
              <surname>Cantu</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Stern</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Clinical subtypes of chronic traumatic encephalopathy: literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome</article-title>
          <source>Alzheimers Res Ther</source>
          <year>2014</year>
          <volume>6</volume>
          <issue>5</issue>
          <fpage>68</fpage>
          <pub-id pub-id-type="doi">10.1186/s13195-014-0068-z</pub-id>
          <pub-id pub-id-type="pmid">25580160</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clark</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chittams</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ewbank</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Peskind</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Galasko</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Morris</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>McKeel</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Farlow</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Weitlauf</surname>
              <given-names>SL</given-names>
            </name>
          </person-group>
          <article-title>Cerebrospinal fluid tau and &#x3B2;-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?</article-title>
          <source>Archives of neurology</source>
          <year>2003</year>
          <volume>60</volume>
          <issue>12</issue>
          <fpage>1696</fpage>
          <lpage>1702</lpage>
          <pub-id pub-id-type="doi">10.1001/archneur.60.12.1696</pub-id>
          <pub-id pub-id-type="pmid">14676043</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Slaets</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Le Bastard</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Theuns</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sleegers</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Verstraeten</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>De Leenheir</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Luyckx</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>J-J</given-names>
            </name>
            <name>
              <surname>Van Broeckhoven</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Engelborghs</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Amyloid pathology influences a&#x3B2;1-42 cerebrospinal fluid levels in dementia with lewy bodies</article-title>
          <source>Journal of Alzheimer&#x2019;s Disease</source>
          <year>2013</year>
          <volume>35</volume>
          <issue>1</issue>
          <fpage>137</fpage>
          <lpage>146</lpage>
          <pub-id pub-id-type="pmid">23364139</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koopman</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Le Bastard</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Nagels</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>De Deyn</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Engelborghs</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Improved discrimination of autopsy-confirmed Alzheimer&#x2019;s disease (AD) from non-AD dementias using CSF P-tau(181P)</article-title>
          <source>Neurochemistry international</source>
          <year>2009</year>
          <volume>55</volume>
          <issue>4</issue>
          <fpage>214</fpage>
          <lpage>218</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neuint.2009.02.017</pub-id>
          <pub-id pub-id-type="pmid">19524111</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bian</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Van Swieten</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Leight</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Massimo</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Forman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>de Koning</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Rosso</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>CSF biomarkers in frontotemporal lobar degeneration with known pathology</article-title>
          <source>Neurology</source>
          <year>2008</year>
          <volume>70</volume>
          <issue>19 Pt 2</issue>
          <fpage>1827</fpage>
          <lpage>1835</lpage>
          <pub-id pub-id-type="doi">10.1212/01.wnl.0000311445.21321.fc</pub-id>
          <pub-id pub-id-type="pmid">18458217</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Toledo</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Brettschneider</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Grossman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Arnold</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>WT</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>SX</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>VM-Y</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Trojanowski</surname>
              <given-names>JQ</given-names>
            </name>
          </person-group>
          <article-title>CSF biomarkers cutoffs: the importance of coincident neuropathological diseases</article-title>
          <source>Acta neuropathologica</source>
          <year>2012</year>
          <volume>124</volume>
          <issue>1</issue>
          <fpage>23</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="doi">10.1007/s00401-012-0983-7</pub-id>
          <pub-id pub-id-type="pmid">22526019</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vemuri</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Simon</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kantarci</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Whitwell</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Senjem</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Przybelski</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Gunter</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Josephs</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Knopman</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Boeve</surname>
              <given-names>BF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND</article-title>
          <source>NeuroImage</source>
          <year>2011</year>
          <volume>55</volume>
          <issue>2</issue>
          <fpage>522</fpage>
          <lpage>531</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neuroimage.2010.12.073</pub-id>
          <pub-id pub-id-type="pmid">21195775</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rabinovici</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Seeley</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Gorno-Tempini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rascovsky</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Pagliaro</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Allison</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Halabi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kramer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Distinct MRI atrophy patterns in autopsy-proven Alzheimer&#x2019;s disease and frontotemporal lobar degeneration</article-title>
          <source>American journal of Alzheimer&#x2019;s disease and other dementias</source>
          <year>2008</year>
          <volume>22</volume>
          <issue>6</issue>
          <fpage>474</fpage>
          <lpage>488</lpage>
          <pub-id pub-id-type="doi">10.1177/1533317507308779</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burton</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Barber</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mukaetova-Ladinska</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Robson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Perry</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jaros</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kalaria</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>O&#x2019;Brien</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Medial temporal lobe atrophy on MRI differentiates Alzheimer&#x2019;s disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis</article-title>
          <source>Brain</source>
          <year>2009</year>
          <volume>132</volume>
          <issue>1</issue>
          <fpage>195</fpage>
          <lpage>203</lpage>
          <pub-id pub-id-type="doi">10.1093/brain/awn298</pub-id>
          <pub-id pub-id-type="pmid">19022858</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kantarci</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lowe</surname>
              <given-names>VJ</given-names>
            </name>
            <name>
              <surname>Boeve</surname>
              <given-names>BF</given-names>
            </name>
            <name>
              <surname>Weigand</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Senjem</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Przybelski</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Dickson</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Parisi</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Knopman</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>GE</given-names>
            </name>
          </person-group>
          <article-title>Multimodality imaging characteristics of dementia with Lewy bodies</article-title>
          <source>Neurobiology of aging</source>
          <year>2012</year>
          <volume>33</volume>
          <issue>9</issue>
          <fpage>2091</fpage>
          <lpage>2105</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2011.09.024</pub-id>
          <pub-id pub-id-type="pmid">22018896</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McKee</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Cantu</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Nowinski</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Hedley-Whyte</surname>
              <given-names>ET</given-names>
            </name>
            <name>
              <surname>Gavett</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Budson</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Santini</surname>
              <given-names>VE</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Kubilus</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Stern</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury</article-title>
          <source>Journal of neuropathology and experimental neurology</source>
          <year>2009</year>
          <volume>68</volume>
          <issue>7</issue>
          <fpage>709</fpage>
          <lpage>735</lpage>
          <pub-id pub-id-type="doi">10.1097/NEN.0b013e3181a9d503</pub-id>
          <pub-id pub-id-type="pmid">19535999</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Minoshima</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Foster</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Sima</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Frey</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Albin</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Kuhl</surname>
              <given-names>DE</given-names>
            </name>
          </person-group>
          <article-title>Alzheimer&#x2019;s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation</article-title>
          <source>Annals of neurology</source>
          <year>2001</year>
          <volume>50</volume>
          <issue>3</issue>
          <fpage>358</fpage>
          <lpage>365</lpage>
          <pub-id pub-id-type="doi">10.1002/ana.1133</pub-id>
          <pub-id pub-id-type="pmid">11558792</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Albin</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Minoshima</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>D&#x2019;Amato</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Frey</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kuhl</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sima</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease</article-title>
          <source>Neurology</source>
          <year>1996</year>
          <volume>47</volume>
          <issue>2</issue>
          <fpage>462</fpage>
          <lpage>466</lpage>
          <pub-id pub-id-type="doi">10.1212/WNL.47.2.462</pub-id>
          <pub-id pub-id-type="pmid">8757021</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Foster</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Heidebrink</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Jagust</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Arnold</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Barbas</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>DeCarli</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Turner</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Koeppe</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Higdon</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer&#x2019;s disease</article-title>
          <source>Brain</source>
          <year>2007</year>
          <volume>130</volume>
          <issue>Pt 10</issue>
          <fpage>2616</fpage>
          <lpage>2635</lpage>
          <pub-id pub-id-type="doi">10.1093/brain/awm177</pub-id>
          <pub-id pub-id-type="pmid">17704526</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bacskai</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Frosch</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Raymond</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Augustinack</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Irizarry</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Klunk</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>Mathis</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>DeKosky</surname>
              <given-names>ST</given-names>
            </name>
          </person-group>
          <article-title>Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report</article-title>
          <source>Archives of neurology</source>
          <year>2007</year>
          <volume>64</volume>
          <issue>3</issue>
          <fpage>431</fpage>
          <lpage>434</lpage>
          <pub-id pub-id-type="doi">10.1001/archneur.64.3.431</pub-id>
          <pub-id pub-id-type="pmid">17353389</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rabinovici</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rosen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Alkalay</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kornak</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Furst</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Agarwal</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Mormino</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>O&#x2019;Neil</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Janabi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Karydas</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD</article-title>
          <source>Neurology</source>
          <year>2011</year>
          <volume>77</volume>
          <issue>23</issue>
          <fpage>2034</fpage>
          <lpage>2042</lpage>
          <pub-id pub-id-type="doi">10.1212/WNL.0b013e31823b9c5e</pub-id>
          <pub-id pub-id-type="pmid">22131541</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghetti</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Oblak</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Boeve</surname>
              <given-names>BF</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Dickerson</surname>
              <given-names>BC</given-names>
            </name>
            <name>
              <surname>Goedert</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging</article-title>
          <source>Neuropathology and applied neurobiology</source>
          <year>2015</year>
          <volume>41</volume>
          <issue>1</issue>
          <fpage>24</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="doi">10.1111/nan.12213</pub-id>
          <pub-id pub-id-type="pmid">25556536</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Braak</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Braak</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Neuropathological stageing of Alzheimer-related changes</article-title>
          <source>Acta neuropathologica</source>
          <year>1991</year>
          <volume>82</volume>
          <issue>4</issue>
          <fpage>239</fpage>
          <lpage>259</lpage>
          <pub-id pub-id-type="doi">10.1007/BF00308809</pub-id>
          <pub-id pub-id-type="pmid">1759558</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Salmon</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Cermak</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Disorders of memory in Alzheimer&#x2019;s disease</article-title>
          <source>Handbook of neuropsychology, Vol 2: Memory and its disorders. Volume 2, edn</source>
          <year>2000</year>
          <publisher-loc>Amsterdam</publisher-loc>
          <publisher-name>Elsevier</publisher-name>
          <fpage>155</fpage>
          <lpage>195</lpage>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seppala</surname>
              <given-names>TT</given-names>
            </name>
            <name>
              <surname>Nerg</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Koivisto</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Rummukainen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Puli</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zetterberg</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Pyykko</surname>
              <given-names>OT</given-names>
            </name>
            <name>
              <surname>Helisalmi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Alafuzoff</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Hiltunen</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings</article-title>
          <source>Neurology</source>
          <year>2012</year>
          <volume>78</volume>
          <issue>20</issue>
          <fpage>1568</fpage>
          <lpage>1575</lpage>
          <pub-id pub-id-type="doi">10.1212/WNL.0b013e3182563bd0</pub-id>
          <pub-id pub-id-type="pmid">22517093</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Landau</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Joshi</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Pontecorvo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mintun</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Trojanowski</surname>
              <given-names>JQ</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Jagust</surname>
              <given-names>WJ</given-names>
            </name>
          </person-group>
          <article-title>Comparing positron emission tomography imaging and cerebrospinal fluid measurements of &#x3B2;&#x2010;amyloid</article-title>
          <source>Annals of neurology</source>
          <year>2013</year>
          <volume>74</volume>
          <issue>6</issue>
          <fpage>826</fpage>
          <lpage>836</lpage>
          <pub-id pub-id-type="doi">10.1002/ana.23908</pub-id>
          <pub-id pub-id-type="pmid">23536396</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blennow</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Zetterberg</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Minthon</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lannfelt</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Strid</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Annas</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Basun</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Andreasen</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Longitudinal stability of CSF biomarkers in Alzheimer&#x2019;s disease</article-title>
          <source>Neuroscience letters</source>
          <year>2007</year>
          <volume>419</volume>
          <issue>1</issue>
          <fpage>18</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neulet.2007.03.064</pub-id>
          <pub-id pub-id-type="pmid">17482358</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mollenhauer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Bibl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wiltfang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Steinacker</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ciesielczyk</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Neubert</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Trenkwalder</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Otto</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1&#x2013;42), and beta-amyloid(1&#x2013;40) in cerebrospinal fluid of patients with dementia with Lewy bodies</article-title>
          <source>Clinical chemistry and laboratory medicine</source>
          <year>2006</year>
          <volume>44</volume>
          <issue>2</issue>
          <fpage>192</fpage>
          <lpage>195</lpage>
          <pub-id pub-id-type="doi">10.1515/CCLM.2006.035</pub-id>
          <pub-id pub-id-type="pmid">16475906</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sexton</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Mackay</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Lonie</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Bastin</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Terri&#xE8;re</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>O&#x2019;Carroll</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Ebmeier</surname>
              <given-names>KP</given-names>
            </name>
          </person-group>
          <article-title>MRI correlates of episodic memory in Alzheimer&#x2019;s disease, mild cognitive impairment, and healthy aging</article-title>
          <source>Psychiatry Research: Neuroimaging</source>
          <year>2010</year>
          <volume>184</volume>
          <issue>1</issue>
          <fpage>57</fpage>
          <lpage>62</lpage>
          <pub-id pub-id-type="doi">10.1016/j.pscychresns.2010.07.005</pub-id>
          <pub-id pub-id-type="pmid">20832251</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Herholz</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Carter</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Positron emission tomography imaging in dementia</article-title>
          <source>The British journal of radiology</source>
          <year>2007</year>
          <volume>80 Spec No 2</volume>
          <fpage>S160</fpage>
          <lpage>167</lpage>
          <pub-id pub-id-type="doi">10.1259/bjr/97295129</pub-id>
          <pub-id pub-id-type="pmid">18445746</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Provenzano</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Jordan</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tikofsky</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Saxena</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Van Heertum</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Ichise</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>F-18 FDG PET imaging of chronic traumatic brain injury in boxers: a statistical parametric analysis</article-title>
          <source>Nuclear medicine communications</source>
          <year>2010</year>
          <volume>31</volume>
          <issue>11</issue>
          <fpage>952</fpage>
          <lpage>957</lpage>
          <pub-id pub-id-type="doi">10.1097/MNM.0b013e32833e37c4</pub-id>
          <pub-id pub-id-type="pmid">20717065</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peskind</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Petrie</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Cross</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Pagulayan</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>McCraw</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hoff</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Raskind</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Cook</surname>
              <given-names>DG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cerebrocerebellar hypometabolism associated with repetitive blast exposure mild traumatic brain injury in 12 Iraq war Veterans with persistent post-concussive symptoms</article-title>
          <source>NeuroImage</source>
          <year>2011</year>
          <volume>54</volume>
          <issue>Suppl 1</issue>
          <fpage>S76</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neuroimage.2010.04.008</pub-id>
          <pub-id pub-id-type="pmid">20385245</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jagust</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Reed</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Mungas</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ellis</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Decarli</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?</article-title>
          <source>Neurology</source>
          <year>2007</year>
          <volume>69</volume>
          <issue>9</issue>
          <fpage>871</fpage>
          <lpage>877</lpage>
          <pub-id pub-id-type="doi">10.1212/01.wnl.0000269790.05105.16</pub-id>
          <pub-id pub-id-type="pmid">17724289</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Landau</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Harvey</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Madison</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Reiman</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Foster</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Aisen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Petersen</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Trojanowski</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Jack</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Comparing predictors of conversion and decline in mild cognitive impairment</article-title>
          <source>Neurology</source>
          <year>2010</year>
          <volume>75</volume>
          <issue>3</issue>
          <fpage>230</fpage>
          <lpage>238</lpage>
          <pub-id pub-id-type="doi">10.1212/WNL.0b013e3181e8e8b8</pub-id>
          <pub-id pub-id-type="pmid">20592257</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Donaghy</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>O&#x2019;Brien</surname>
              <given-names>JT</given-names>
            </name>
          </person-group>
          <article-title>Amyloid PET Imaging in Lewy body disorders</article-title>
          <source>The American journal of geriatric psychiatry</source>
          <year>2015</year>
          <volume>23</volume>
          <issue>1</issue>
          <fpage>23</fpage>
          <lpage>37</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jagp.2013.03.001</pub-id>
          <pub-id pub-id-type="pmid">23831180</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rowe</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ackermann</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Gong</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pike</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Savage</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cowie</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Dickinson</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Maruff</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Darby</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Imaging &#x3B2;-amyloid burden in aging and dementia</article-title>
          <source>Neurology</source>
          <year>2007</year>
          <volume>68</volume>
          <issue>20</issue>
          <fpage>1718</fpage>
          <lpage>1725</lpage>
          <pub-id pub-id-type="doi">10.1212/01.wnl.0000261919.22630.ea</pub-id>
          <pub-id pub-id-type="pmid">17502554</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Engler</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Santillo</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>SX</given-names>
            </name>
            <name>
              <surname>Lindau</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Savitcheva</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Nordberg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lannfelt</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Langstrom</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kilander</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>In vivo amyloid imaging with PET in frontotemporal dementia</article-title>
          <source>Eur J Nucl Med Mol Imaging</source>
          <year>2008</year>
          <volume>35</volume>
          <issue>1</issue>
          <fpage>100</fpage>
          <lpage>106</lpage>
          <pub-id pub-id-type="doi">10.1007/s00259-007-0523-1</pub-id>
          <pub-id pub-id-type="pmid">17846768</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McKee</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Stern</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Nowinski</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Alvarez</surname>
              <given-names>VE</given-names>
            </name>
            <name>
              <surname>Daneshvar</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Wojtowicz</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Baugh</surname>
              <given-names>CM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The spectrum of disease in chronic traumatic encephalopathy</article-title>
          <source>Brain</source>
          <year>2013</year>
          <volume>136</volume>
          <issue>Pt 1</issue>
          <fpage>43</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="doi">10.1093/brain/aws307</pub-id>
          <pub-id pub-id-type="pmid">23208308</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Curtis</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gamez</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Sadowsky</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Villena</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sabbagh</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Beach</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Duara</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fleisher</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Frey</surname>
              <given-names>KA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density</article-title>
          <source>JAMA neurology</source>
          <year>2015</year>
          <volume>72</volume>
          <issue>3</issue>
          <fpage>287</fpage>
          <lpage>294</lpage>
          <pub-id pub-id-type="doi">10.1001/jamaneurol.2014.4144</pub-id>
          <pub-id pub-id-type="pmid">25622185</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <mixed-citation publication-type="other">Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, Senda K, Murayama S, Ishii K, Takao M. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer disease: Phase 3 study. Alzheimer&#x2019;s &amp; Dementia. 2015;11(8):964-74</mixed-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clark</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Pontecorvo</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Beach</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Bedell</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Coleman</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Doraiswamy</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Fleisher</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Reiman</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Sabbagh</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Sadowsky</surname>
              <given-names>CH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-&#x3B2; plaques: a prospective cohort study</article-title>
          <source>The Lancet Neurology</source>
          <year>2012</year>
          <volume>11</volume>
          <issue>8</issue>
          <fpage>669</fpage>
          <lpage>678</lpage>
          <pub-id pub-id-type="doi">10.1016/S1474-4422(12)70142-4</pub-id>
          <pub-id pub-id-type="pmid">22749065</pub-id>
        </element-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nelson</surname>
              <given-names>PT</given-names>
            </name>
            <name>
              <surname>Alafuzoff</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Bigio</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Bouras</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Braak</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Cairns</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Castellani</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Crain</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Del Tredici</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature</article-title>
          <source>Journal of neuropathology and experimental neurology</source>
          <year>2012</year>
          <volume>71</volume>
          <issue>5</issue>
          <fpage>362</fpage>
          <lpage>381</lpage>
          <pub-id pub-id-type="doi">10.1097/NEN.0b013e31825018f7</pub-id>
          <pub-id pub-id-type="pmid">22487856</pub-id>
        </element-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gomperts</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Marquie</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Locascio</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Bayer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Growdon</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
          <article-title>PET Radioligands Reveal the Basis of Dementia in Parkinson&#x2019;s Disease and Dementia with Lewy Bodies</article-title>
          <source>Neurodegenerative Diseases</source>
          <year>2016</year>
          <volume>16</volume>
          <issue>1&#x2013;2</issue>
          <fpage>118</fpage>
          <lpage>124</lpage>
          <pub-id pub-id-type="pmid">26655867</pub-id>
        </element-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mitsis</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Riggio</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kostakoglu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Dickstein</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Machac</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Delman</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Goldstein</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jennings</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>D&#x2019;Antonio</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury</article-title>
          <source>Translational psychiatry</source>
          <year>2014</year>
          <volume>4</volume>
          <fpage>e441</fpage>
          <pub-id pub-id-type="doi">10.1038/tp.2014.91</pub-id>
          <pub-id pub-id-type="pmid">25226550</pub-id>
        </element-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Minoshima</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Frey</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Koeppe</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Foster</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Kuhl</surname>
              <given-names>DE</given-names>
            </name>
          </person-group>
          <article-title>A diagnostic approach in Alzheimer&#x2019;s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET</article-title>
          <source>Journal of Nuclear Medicine</source>
          <year>1995</year>
          <volume>36</volume>
          <issue>7</issue>
          <fpage>1238</fpage>
          <lpage>1248</lpage>
          <pub-id pub-id-type="pmid">7790950</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
